# Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

> **NCT06684743** · PHASE4 · RECRUITING · sponsor: **Tor Biering-Sørensen** · enrollment: 690000 (estimated)

## Conditions studied

- RSV

## Interventions

- **BIOLOGICAL:** RSV prefusion F protein-based vaccine

## Key facts

- **NCT ID:** NCT06684743
- **Lead sponsor:** Tor Biering-Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-18
- **Primary completion:** 2028-05
- **Final completion:** 2028-08
- **Target enrollment:** 690000 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06684743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06684743, "Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06684743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*